Skip to main content

Osteoporosis, Postmenopausal

23
Pipeline Programs
16
Companies
35
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
1
0
0
12
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1260%
Monoclonal Antibody
840%
+ 26 programs with unclassified modality

On Market (1)

Approved therapies currently available

Eli Lilly and Company
FORTEOApproved
teriparatide
Eli Lilly and Company
Parathyroid Hormone Analog [EPC]subcutaneous2002
425M Part D

Competitive Landscape

16 companies ranked by most advanced pipeline stage

Prevail Therapeutics
14 programs
3
7
3
TeriparatidePhase 4Peptide1 trial
teriparatidePhase 4Peptide1 trial
teriparatidePhase 4Peptide1 trial
ArzoxifenePhase 31 trial
ArzoxifenePhase 31 trial
+9 more programs
Active Trials
NCT00696644Completed794Est. Apr 2011
NCT02109042Completed15Est. Jul 2014
NCT02337387Terminated28Est. Mar 2015
+11 more trials
ViiV Healthcare
ViiV HealthcareNC - Durham
6 programs
3
1
IbandronatePhase 4
DenosumabPhase 3Monoclonal Antibody
denosumabPhase 3Monoclonal Antibody
denosumabPhase 3Monoclonal Antibody
Fracture evaluationN/A
+1 more programs
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
4 programs
1
TeriparatideN/APeptide
BlosozumabPHASE_1Monoclonal Antibody
teriparatidePHASE_3Peptide
teriparatidePHASE_4Peptide
Pfizer
PfizerNEW YORK, NY
2 programs
1
BazedoxifenePhase 41 trial
BazedoxifeneN/A1 trial
Active Trials
NCT01416194Completed10,497Est. Apr 2019
NCT02090400Completed110Est. Jul 2015
Alvotech
AlvotechLUXEMBOURG, Luxembourg
1 program
1
AVT03Phase 31 trial
Active Trials
NCT05395091Completed532Est. Oct 2024
Luye Pharma
Luye PharmaChina - Shanghai
1 program
1
DenosumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT05853354Unknown392Est. Dec 2025
Purdue Pharma
Purdue PharmaCT - Stamford
3 programs
1
Blueberry BaselinePhase 1/21 trial
0 g SCFN/A1 trial
Hesperidin and CalcilockN/A1 trial
Active Trials
NCT02416947Completed14Est. Jan 2015
NCT01881204Completed12Est. Oct 2012
NCT02630797Unknown20Est. Aug 2019
Huons
HuonsKorea - Seongnam
1 program
1
HUG186-B and HUG186-DPhase 11 trial
Active Trials
NCT03475719Unknown52Est. Apr 2018
Radius Health
Radius HealthMA - Boston
3 programs
AbaloparatideN/APeptide1 trial
AbaloparatidePHASE_3Peptide1 trial
Denosumab InjectionPHASE_41 trial
Active Trials
NCT04974723Completed22,054Est. Sep 2021
NCT03710889Completed23Est. Jul 2020
NCT04467983Active Not Recruiting70Est. Dec 2026
Bayer
BayerLEVERKUSEN, Germany
3 programs
E2 transdermalN/A1 trial
E2 transdermalN/A1 trial
E2/LNG oralN/A1 trial
Active Trials
NCT01397955Completed148Est. Apr 2014
NCT01386281Completed506Est. Apr 2014
NCT01401114Completed411Est. Sep 2014
GSK
GSKLONDON, United Kingdom
3 programs
Fracture evaluationN/A1 trial
OPSAT-QN/A1 trial
IbandronatePHASE_41 trial
Active Trials
NCT01381588Completed1,136Est. Feb 2011
NCT01227369Completed4,376Est. Nov 2009
NCT00405392Completed365Est. May 2008
Bone Index
Bone IndexFinland - Kuopio
1 program
Bindex measurementN/A1 trial
Active Trials
NCT03878732Completed293Est. Feb 2020
Labatec Pharma
Labatec PharmaSwitzerland - Geneva
1 program
Binosto 70Mg Effervescent TabletN/A1 trial
Active Trials
NCT03435094Unknown80Est. Dec 2022
One Biosciences
One BiosciencesFrance - Paris
1 program
DenosumabN/AMonoclonal Antibody
Nordic Pharma
Nordic PharmaFrance - Paris
1 program
ProbioticN/A1 trial
Active Trials
NCT06375668Completed170Est. Jun 2024
Sanofi
SanofiPARIS, France
1 program
Risedronate SodiumPHASE_41 trial
Active Trials
NCT00632216Completed464Est. May 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Radius HealthDenosumab Injection
PfizerBazedoxifene
Prevail Therapeuticsteriparatide
GSKIbandronate
SanofiRisedronate Sodium
Prevail TherapeuticsTeriparatide
Prevail Therapeuticsteriparatide
Luye PharmaDenosumab
AlvotechAVT03
Radius HealthAbaloparatide
Prevail TherapeuticsArzoxifene
Prevail Therapeuticsteriparatide
Prevail TherapeuticsArzoxifene
Prevail Therapeuticsteriparatide 20 micrograms/day subcutaneous
Prevail Therapeuticsteriparatide

Showing 15 of 34 trials with date data

Clinical Trials (35)

Total enrollment: 63,801 patients across 35 trials

NCT04467983Radius HealthDenosumab Injection

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

Start: Feb 2021Est. completion: Dec 202670 patients
Phase 4Active Not Recruiting
NCT02090400PfizerBazedoxifene

Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women

Start: May 2013Est. completion: Jul 2015110 patients
Phase 4Completed

A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide

Start: Nov 2007Est. completion: May 201135 patients
Phase 4Completed
NCT00405392GSKIbandronate

Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis

Start: Mar 2007Est. completion: May 2008365 patients
Phase 4Completed
NCT00632216SanofiRisedronate Sodium

A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis

Start: May 2004Est. completion: May 2006464 patients
Phase 4Completed

2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis

Start: Aug 2002Est. completion: Nov 2005810 patients
Phase 4Completed

Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis

Start: Oct 2001Est. completion: Jul 2005330 patients
Phase 4Completed

Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis

Phase 3Completed

Comparative Efficacy, Safety, PK, and Immunogenicity Study

Start: Apr 2023Est. completion: Dec 2025392 patients
Phase 3Unknown

Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND

Start: Aug 2022Est. completion: Oct 2024532 patients
Phase 3Completed

Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption

Start: Sep 2018Est. completion: Jul 202023 patients
Phase 3Completed

Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis

Start: Oct 2006Est. completion: Jul 2008320 patients
Phase 3Completed

Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis

Start: Jun 2006Est. completion: Jun 2010712 patients
Phase 3Completed

Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer

Start: Jun 2004Est. completion: Nov 20099,369 patients
Phase 3Completed
NCT00542984Prevail Therapeuticsteriparatide 20 micrograms/day subcutaneous

Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis

Start: Aug 2003Est. completion: Nov 200470 patients
Phase 3Completed

Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

Start: Aug 1996Est. completion: Apr 19991,637 patients
Phase 3Completed

Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis

Start: Nov 1994Est. completion: Sep 19997,705 patients
Phase 3Completed
NCT02630797Purdue PharmaBlueberry Baseline

Effect of Blueberries on Bone Turnover

Start: Jan 2017Est. completion: Aug 201920 patients
Phase 1/2Unknown
NCT03475719HuonsHUG186-B and HUG186-D

A Clinical Trial to Evaluate the Safety and Pharmacokinetic

Start: Jan 2018Est. completion: Apr 201852 patients
Phase 1Unknown

A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

Start: Jan 2015Est. completion: Mar 201528 patients
Phase 1Terminated

A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants

Start: Apr 2014Est. completion: Jul 201415 patients
Phase 1Completed

A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women

Start: Nov 2010Est. completion: May 2011251 patients
Phase 1Completed

The Effect of the Probiotic Strains on Bone Mineral Density in Postmenopausal Women

Start: Mar 2022Est. completion: Jun 2024170 patients
N/ACompleted

Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

Start: Jul 2021Est. completion: Sep 202122,054 patients
N/ACompleted
NCT03878732Bone IndexBindex measurement

Bindex for Osteoporosis Diagnostics

Start: Mar 2019Est. completion: Feb 2020293 patients
N/ACompleted
NCT03435094Labatec PharmaBinosto 70Mg Effervescent Tablet

Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes

Start: Feb 2018Est. completion: Dec 202280 patients
N/AUnknown

Soluble Corn Fiber Effect on Bone Resorption in Post Menopausal Women

Start: Mar 2012Est. completion: Jan 201514 patients
N/ACompleted
NCT01416194PfizerBazedoxifene

Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)

Start: Jul 2011Est. completion: Apr 201910,497 patients
N/ACompleted
NCT01881204Purdue PharmaHesperidin and Calcilock

Hesperidin and Bone Health in Postmenopausal Women

Start: Apr 2011Est. completion: Oct 201212 patients
N/ACompleted
NCT01381588GSKFracture evaluation

The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women

Start: Oct 2010Est. completion: Feb 20111,136 patients
N/ACompleted
NCT01401114BayerE2/LNG oral

Wellnara Post-marketing Surveillance in Japan

Start: Mar 2009Est. completion: Sep 2014411 patients
N/ACompleted
NCT01397955BayerE2 transdermal

Julina Post-marketing Surveillance for Postmenopausal Osteoporosis in Japan

Start: Jan 2009Est. completion: Apr 2014148 patients
N/ACompleted
NCT01386281BayerE2 transdermal

Julina Post-marketing Surveillance for Climacteric Symptoms in Japan

Start: Oct 2008Est. completion: Apr 2014506 patients
N/ACompleted

A Study for Teriparatide in Severe Osteoporosis

Start: Jun 2008Est. completion: Apr 2011794 patients
N/ACompleted

Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment

Start: Jun 2008Est. completion: Nov 20094,376 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

12 late-stage (Phase 3) programs, potential near-term approvals
16 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.